Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies.

ABSTRACT:

Introduction

In patients with pro-opiomelanocortin (POMC) or leptin receptor (LEPR) deficiency, managing obesity and hyperphagia can be burdensome for patients and caretakers. The impacts on health-related quality of life are under-recognized and are not well characterized.

Methods

We conducted in-depth qualitative interviews in patients with POMC (n = 3) and LEPR (n = 2) deficiencies participating in an ongoing open-label extension of phase 3 clinical trials with the melanocortin receptor 4 agonist setmelanotide to describe the patient experience of hyperphagia and characterize changes following treatment with setmelanotide.

Results

Prior to setmelanotide treatment, all five patients described abnormal sensations of hunger with none indicating feeling satiated after

SUBMITTER: Wabitsch M 

PROVIDER: S-EPMC8862005 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature